Evoke Pharma, Inc. (EVOK)
EVOK was initiated with a Buy and price target of $60.00 by brokerage firm Aegis Capital.. Shares of EVOK soared $ 3.59 (or +44.05%) to $11.74 on Tuesday's market activity.
On September 24, 2013, EVOK priced its initial public offering of 2.1 million shares of common stock at $12.00 per share. On October 3, 2013, the underwriters exercised their over-allotment to purchase an additional 315,000 shares of common stock. The exercise resulted in estimated total net proceeds of $25.1 million, after deducting expenses and underwriting discounts.
Diabetic gastroparesis is a gastrointestinal disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms.
EVOK is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. By offering a product that can bypass the stomach and directly enter the systemic circulation, EVK-001 potentially allows a more predictable means of delivering the-drug
EVOK is a specialty pharmaceutical company focused primarily on the development of drugs-to treat gastrointestinal disorders and diseases.
More about Evoke Pharma, Inc. (EVOK) at www.evokepharma.com
**
Crown Equity Holdings Inc. (CRWE)
B2B (business to business) is the term for transactions between businesses for example a manufacturer and a wholesaler, or between a wholesaler and a retailer.
More than half, 57%, of business buyers have purchased goods for their companies online, and 37% said they expect to spend a bigger proportion of their annual procurement budgets online next year, according to Acquity Group LLC’s 2013 State of B2B Procurement Study.
U.S. companies and government agencies will purchase $559 billion via the web in 2013, Forrester Research Inc. predicted in its first estimate of the b2b e-commerce market released last year.
CRWE is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar online b2b market.
Strategic plans are being developed for CRWE ’s iB2B Global project.
Shares of CRWE closed at $0.009, up $0.004 (or +80%).
As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
**
Qiwi plc (QIWI)
The price of QIWI stock surged $2.69 (or +6.40%) to $44.73 per share on Tuesday's trading session, after the company reported another strong quarter on its financial results.
For the third quarter 2013, QIWI posted adjusted net revenue of RUB 1,622 million ($50.2 million), a 49% increase compared to the same period the prior year, and adjusted net profit of RUB 605 million ($18.7 million), a 56% increase year over year.
According to its 2013 guidance, QIWI 's adjusted net revenue is expected to increase by 42% to 45% over 2012, above the previous guidance of 27% to 30%, while its adjusted net profit is expected to increase by 50% to 55% over 2012, above the previous guidance of 35% to 40%.
QIWI is a leading provider of next generation payment services in Russia and the CIS. It has an integrated proprietary network that enables payment services across physical, online and mobile channels.
More about Qiwi plc (QIWI) at www.qiwi.ru
**
Read Full Disclaimer at www.mikezaman.com/disclaimer
